Prospective random controlled clinic study of high-doses of angiotensin-converting enzyme inhibitor benazapril in patients of chronic kidney diseases with proteinuria
GUO Dong-yang
ZHANG Fan
WANG Tao
ZHANG Guang-ming
ZHEN Yu
ZHU Chang-liang
Abstract：Objective To evaluate the antiproteinuric effect and safety of highdose ACE for hibitor benazapril for patients of chronic kiclney diseases with proteinuria. Methods A prospective random controlled clinical trail was performed. Seventy-nine patients were divided into two groups in this 24-week study (coutrd group 32 cases, trial group 35 patients). These patients were recorded of age, sex, pathogeny, 24 hour unnary protein excretion, serum albumin concentration and serum creatinine concentration (P>0.05). All received cortical hormone,or cortical hormone and CTX, or only dipyridamole and piperazine ferulate.The trial group received extra orally 30～40 mg/d benazapril for 24 weeks. Results In control group, nineteen patients had complete remission, 10 partial remission,4 partial effect and 2 no effect in trial group. In control group, forteen complete remission,9 partial remission,5 partial effect and 4 no effect in control group. Proteinuria decreased significantly from baseline urinay protein excretion of (2.67±1.32)tg/24 h to (0.67±0.58)g/24 h in trial group (P<0.01) . Proteinuria decreased significantly from baseline protein excretion of (2.74±1.29) g/24 h to (0.94±0.73) g/24 h in control group (P<0.01) . The urinay protein excretion was statistically different between trial group and control group (P<0.05). There was no differece between trial group and control group in blood pressure and blood serum creatinine (P<0.05). Conclusion A highdose ACE inhibitor, benazapril can safely reduce proteinuria in patients with chronic kidney diseases.
Keywords：Chronic kidney disease Angiotensin-eonverting enzyme inhibitorBenazapril
Publication Date：2008-01-01
Online Publishing Date：2026-09-14(First online date of this platform, not the publication date of the document)
Pages：2( 594-595 )